Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 5/20 | 0.51 |
| ▸ | NPY4R | P50391 | 6/20 | 0.49 |
| ▸ | NPY1R | P25929 | 5/20 | 0.49 |
| ▸ | NPY2R | P49146 | 5/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.46 |
| ▸ | MC4R | P32245 | 2/20 | 0.45 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.44 |
| ▸ | PRKACB | P22694 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19717735 | 0.95 | CTSC (0.55) | CTSCNPY4RNPY1RNPY2R | |
| SCHEMBL1649662 | 0.95 | CTSC (0.55) | CTSCNPY4RNPY1RNPY2R | |
| SCHEMBL1693501 | 0.93 | KISS1R (0.51) | MC4RKISS1R | |
| SCHEMBL28176391 | 0.93 | KISS1R (0.51) | MC4RKISS1R | |
| SCHEMBL27745741 | 0.90 | GHSR (0.49) | CTSCPRKACB | |
| SCHEMBL29924965 | 0.89 | ACE (0.55) | NPY4RNPY1RNPY2R | |
| SCHEMBL29662004 | 0.89 | ACE (0.55) | NPY4RNPY1RNPY2R | |
| SCHEMBL31193767 | 0.89 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5RMC4R | |
| SCHEMBL31193750 | 0.89 | NPY4R (0.58) | NPY4RNPY1RNPY2RNPY5RMC4R | |
| SCHEMBL29924961 | 0.89 | ACE (0.55) | NPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CTSC 331/4885NPY4R 567/4885NPY1R 544/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | CTSC 383/4885NPY4R 2480/4885NPY1R 3329/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CTSC 331/4885NPY4R 567/4885NPY1R 544/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | CTSC 157/4885NPY4R 915/4885NPY1R 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.